XML 45 R33.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2025
Segment Information [Abstract]  
Segment Information

The following table sets forth information on segment profit or loss, including significant segment expenses (in thousands):

 
Three Months Ended
March 31,
  
   
2025
    
2024
  
Revenue
  
$
131,612
    
$
119,497
  
                 
Less:
                
Cost of sales
    
1,363
      
1,952
  
Drug discovery
    
26,989
      
28,171
  
Drug development
    
112,946
      
125,751
  
Medical affairs
    
5,642
      
4,676
  
Manufacturing and development chemistry
    
14,281
      
11,441
  
R&D support
    
20,553
      
21,946
  
Selling, general and administrative
    
66,980
      
43,733
  
Other segment items (1)
    
29,796
      
24,630
  
                 
Consolidated net loss
  
$
(146,938
)
  
$
(142,803
)

(1)
Other segment items include stock-based compensation expense, investment income, interest expense, gain or loss on investments, other income or expense and income tax expense or benefit.